就在刚刚，美国突然宣布了 9月27日，美高层用三个字把全球市场砸醒，印度难受了

Group 1 - The U.S. government's announcement of a 100% tariff on patented drugs has caused significant turmoil in global markets, leading to declines in U.S. stock futures and a drop in pharmaceutical stocks across Asia-Pacific, with Australia's CSL reaching a six-year low [1][3] - Pharmaceutical companies are faced with a dilemma: to maintain access to the U.S. market, they must invest heavily in relocating production facilities to the U.S., or risk losing profits due to the 100% tariff [3] - Indian pharmaceutical companies are particularly affected, with $8.7 billion in drug exports to the U.S. in FY2024, accounting for 31% of their total exports, and over 30% of their revenue dependent on the U.S. market [4] Group 2 - The U.S. strategy of imposing tariffs to gain economic advantage is likely to backfire, potentially leading to retaliatory measures from other countries and harming normal trade relations, which could isolate the U.S. and diminish its economic benefits [6]